Other papers submitted by: Dr Dmitry Galkin

open access to scientific and medical research

News:

Expressions of interest for Editor-in-Chief - the International Medical Case Reports Journal Read more

Back to User profile » Dr Dmitry Galkin

Papers published by Dr Dmitry Galkin:

Original Research

Highly-accessed

Plain language summary

Clinical burden of illness among patients with severe eosinophilic COPD

Müllerová H, Meeraus WH, Galkin DV, Albers FC, Landis SH

International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:741-755

Published Date: 28 March 2019

Original Research

Highly-accessed

Predictors of pneumonia on routine chest radiographs in patients with COPD: a post hoc analysis of two 1-year randomized controlled trials

Rubin DB, Ahmad HA, O'Neal M, Bennett S, Lettis S, Galkin DV, Crim C

International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:189-201

Published Date: 8 January 2018

Original Research

Highly-accessed

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study

Kerwin EM, Kalberg CJ, Galkin DV, Zhu C, Church A, Riley JH, Fahy WA

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:745-755

Published Date: 24 February 2017

Original Research

Highly-accessed

Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation

Chuchalin AG, Khaltaev N, Antonov NS, Galkin DV, Manakov LG, Antonini P, Murphy M, Solodovnikov AG, Bousquet J, Pereira MHS, Demko IV

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:963-974

Published Date: 12 September 2014

Original Research

Noteworthy Comment: This paper is one of the very first to not only clearly confirm the finding that inhaled steroids in COPD increase the risk of pneumonia but it also describes the some possible sub groups of patients who are at increased risk. This should aid the clinician in making decisions as to when and if to start inhaled steroids. Moreover we need to not only phenotype our patients for their possible responsiveness but also for their risk of significant harm due in part to medication, in this instance pneumonia driven by inhaled steroids.

Highly-accessed

Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis

DiSantostefano RL, Li H, Hinds D, Galkin DV, Rubin DB

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:457-468

Published Date: 7 May 2014